ADIL
HEALTHCAREAdial Pharmaceuticals Inc
$1.58-0.02 (-1.25%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ADIL Today?
No stock-specific AI insight has been generated for ADIL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.38$18.90
$1.58
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-11.93
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume141K
Avg Volume (10D)—
Shares Outstanding1.4M
ADIL News
21 articles- Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045Yahoo Finance·Apr 29, 2026
- Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsightGlobeNewswire Inc.·Apr 27, 2026
- Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development ProgramYahoo Finance·Apr 27, 2026
- Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 TrialYahoo Finance·Apr 22, 2026
- Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for VeteransYahoo Finance·Mar 24, 2026
- Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business UpdateYahoo Finance·Mar 6, 2026
- Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive AgreementYahoo Finance·Mar 3, 2026
- Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing RequirementYahoo Finance·Feb 24, 2026
- Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to OneYahoo Finance·Feb 23, 2026
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 17, 2026
- Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04Yahoo Finance·Feb 4, 2026
- Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price RequirementYahoo Finance·Feb 3, 2026
- Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045Yahoo Finance·Jan 14, 2026
- Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?Yahoo Finance·Jan 6, 2026
- Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross ProceedsYahoo Finance·Nov 26, 2025
- Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 14, 2025
- Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz ShowYahoo Finance·Oct 17, 2025
- Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing SolutionYahoo Finance·Oct 9, 2025
- CoreWeave initiated, Instacart downgraded: Wall Street's top analyst callsYahoo Finance·Sep 30, 2025
- Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use DisorderYahoo Finance·Sep 16, 2025
- Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04Yahoo Finance·Sep 16, 2025
All 21 articles loaded
Price Data
Open$1.61
Previous Close$1.60
Day High$1.65
Day Low$1.56
52 Week High$18.90
52 Week Low$1.38
52-Week Range
$1.38$18.90
$1.58
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-11.93
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume141K
Avg Volume (10D)—
Shares Outstanding1.4M
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—